Modality
ADC
MOA
MALT1i
Target
B7-H3
Pathway
Epigenetic
HSMSCF
Development Pipeline
Preclinical
~Nov 2022
→ ~Feb 2024
Phase 1
~May 2024
→ ~Aug 2025
Phase 2
Nov 2025
→ Feb 2028
Phase 2Current
NCT05477615
2,869 pts·HS
2025-11→2028-02·Terminated
2,869 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-061.9y awayPh2 Data· HS
Trial Timeline
2026Q2Q3Q42027Q2Q3Q42028
P2
Termina…
Catalysts
Ph2 Data
2028-02-06 · 1.9y away
HS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05477615 | Phase 2 | HS | Terminated | 2869 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 |